These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 20149229)

  • 1. A mouse model for the Sézary syndrome.
    Doebbeling U
    J Exp Clin Cancer Res; 2010 Feb; 29(1):11. PubMed ID: 20149229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel mouse model for Sézary syndrome using xenotransplantation of Sézary cells into immunodeficient RAG2(-/-) γc(-/-) mice.
    van der Fits L; Rebel HG; Out-Luiting JJ; Pouw SM; Smit F; Vermeer KG; van Zijl L; Tensen CP; Weijer K; Vermeer MH
    Exp Dermatol; 2012 Sep; 21(9):706-9. PubMed ID: 22897578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of AAC-11-Derived Peptide Anti-Tumor Activity in a Single Graft Sézary Patient-Derived Xenograft Mouse Model.
    Habault J; Thonnart N; Ram-Wolff C; Bagot M; Bensussan A; Poyet JL; Marie-Cardine A
    Cells; 2022 Sep; 11(19):. PubMed ID: 36230895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sézary syndrome without erythroderma.
    Henn A; Michel L; Fite C; Deschamps L; Ortonne N; Ingen-Housz-Oro S; Marinho E; Beylot-Barry M; Bagot M; Laroche L; Crickx B; Maubec E
    J Am Acad Dermatol; 2015 Jun; 72(6):1003-9.e1. PubMed ID: 25981000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deficiency of SATB1 expression in Sezary cells causes apoptosis resistance by regulating FasL/CD95L transcription.
    Wang Y; Su M; Zhou LL; Tu P; Zhang X; Jiang X; Zhou Y
    Blood; 2011 Apr; 117(14):3826-35. PubMed ID: 21270445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Xenograft and cell culture models of Sézary syndrome reveal cell of origin diversity and subclonal heterogeneity.
    Poglio S; Prochazkova-Carlotti M; Cherrier F; Gros A; Laharanne E; Pham-Ledard A; Beylot-Barry M; Merlio JP
    Leukemia; 2021 Jun; 35(6):1696-1709. PubMed ID: 33106625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for an oncogenic role of AHI-1 in Sezary syndrome, a leukemic variant of human cutaneous T-cell lymphomas.
    Ringrose A; Zhou Y; Pang E; Zhou L; Lin AE; Sheng G; Li XJ; Weng A; Su MW; Pittelkow MR; Jiang X
    Leukemia; 2006 Sep; 20(9):1593-601. PubMed ID: 16838023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.
    Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E
    Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SNF5 deficiency induces apoptosis resistance by repressing SATB1 expression in Sézary syndrome.
    Li Y; Wang J; Yu M; Wang Y; Zhang H; Yin J; Li Z; Li T; Yan H; Li F; Wang X
    Leuk Lymphoma; 2018 Oct; 59(10):2405-2413. PubMed ID: 29334836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The emergence of Sézary cells during the treatment of cutaneous T-cell lymphoma.
    Sato M; Ishikawa O; Miyachi Y
    Br J Dermatol; 1995 Nov; 133(5):810-3. PubMed ID: 8555042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicompartment analysis of cell proliferation and cell migration in the Sezary syndrome.
    Shackney SE; Schuette WH
    Hematol Oncol; 1983; 1(1):31-48. PubMed ID: 6677561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of the candidate tumor suppressor ZEB1 (TCF8, ZFHX1A) in Sézary syndrome.
    Caprini E; Bresin A; Cristofoletti C; Helmer Citterich M; Tocco V; Scala E; Monopoli A; Benucci R; Narducci MG; Russo G
    Cell Death Dis; 2018 Dec; 9(12):1178. PubMed ID: 30518749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New developments in Sézary syndrome].
    Caudron A; Marie-Cardine A; Bensussan A; Bagot M
    Ann Dermatol Venereol; 2012 Jan; 139(1):31-40. PubMed ID: 22225740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aneuploid malignant T cells from a patient with Sézary syndrome can be visualized by in situ hybridization.
    Hindkjaer J; Brandt CA; Kaltoft K
    Arch Dermatol; 1993 Sep; 129(9):1141-5. PubMed ID: 8363397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sézary Syndrome Presenting With Renal Involvement.
    Wickenden K; Graham-Brown MPM; Veitch D; Dormer J; Bamford M; Graham-Brown RAC; Warwick G; Wagner S; Burton JO
    Am J Kidney Dis; 2018 Dec; 72(6):890-894. PubMed ID: 29941220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sézary syndrome. A malignant leukemic reticuloendotheliosis.
    Tedeschi LG; Lansinger DT
    Arch Dermatol; 1965 Sep; 92(3):257-62. PubMed ID: 11851246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurolymphomatosis associated with Sézary syndrome.
    Bezier M; Reguiaï Z; Delaby P; Laroche L; Saïd G; Bernard P; Grange F
    Arch Dermatol; 2009 Mar; 145(3):294-6. PubMed ID: 19289760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biclonal Sézary syndrome with capillary leak syndrome.
    Dereure O; Portales P; Clot J; Guilhou JJ
    Dermatology; 1994; 188(2):152-6. PubMed ID: 8136545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bilateral breast involvement in Sézary syndrome.
    Balci P; Undar B; Yilmaz E; Seçil M; Ozsan H; Canda T
    Eur Radiol; 2001; 11(12):2468-71. PubMed ID: 11734942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening tests for Sezary cells in cutaneous T-cell lymphomas.
    Newton JA; Guthrie DL; Westwood NB; Pearson TC; Camplejohn RS; Smith N
    Clin Lab Haematol; 1986; 8(2):109-14. PubMed ID: 3488168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.